Nektar Therapeutics – Value Analysis (NASDAQ:NKTR) : January 6, 2017
Categories: Fundamental Analysis Yahoo Finance Click here to see latest analysis Capitalcube gives Nektar Therapeutics a score of 21. Our analysis is based on comparing Nektar Therapeutics with the following peers – Amgen Inc., Pfizer Inc., Merck & Co., Inc., Enzon Pharmaceuticals, Inc., Johnson & Johnson, Astrazeneca PLC Sponsored ADR, Richardson Electronics, Ltd., Affymax, Inc., Alkermes Plc and Baxter International ... Read more (Read more...)